Among the highlights of the ESC 2024 Congress (29 August-2 September, London, UK, and online), expert lipid specialists discussed latest progress in understanding of the role of Lp(a) in aortic stenosis, the benefits of Lp(a) testing on lipid control, the potential need for repeat Lp(a) measurement, implications of elevated Lp(a) for coronary calcium score, and […]
Growing evidence supports a role for Lp(a) in both initiation and progression of aortic valve stenosis (AVS), with potential for novel medical interventions before valve replacement is needed. This was the key message to emerge from a series of presentations on Lp(a) and AVS that included biological, Mendelian randomisation and epidemiological data linking Lp(a) to […]
A single combined measure of hsCRP, LDL-C, and Lp(a) can predict incident cardiovascular events across a 30-year period, and has potential for extending strategies for primary prevention of atherosclerotic events.
Patients with atherosclerotic cardiovascular disease (ASCVD) who have their Lp(a) measured are more likely to achieve recommended target LDL-C levels than those who do not have their Lp(a) measured, according to data from the PREVAIL study of Lp(a) testing in 55,427 patients with ASCVD in Australia.
A repeat Lp(a) measurement may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial test result is in the intermediate ‘grey-zone’ as defined by the European Atherosclerosis Society guidelines.1,2
Elevated Lp(a) level has been linked to increased coronary artery calcium (CAC) score and progression of atherosclerosis in STAR-Lp(a) – a cohort study of 553 patients with risk factors for cardiovascular disease (CVD) but without evidence of disease.
